Dana-Farber Cancer Institute: Breast Neoplasms trials

The registry lists 134 Breast Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 15 are open to participants now and 54 have results posted.

Early Phase 1 2Phase 1 21Phase 2 59Phase 3 2No phase 54(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clonal Hematopoiesis Chemotherapy and Radiation Effects StudyRecruitingNCT07675967
• Breast and Cervical Cancer Stigma in RwandaNot yet recruitingNCT07663006Not applicable
• Adjuvant Endocrine Therapy Adherence Intervention Pilot in RwandaNot yet recruitingNCT07562399Not applicable
• Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNot yet recruitingNCT07499999Phase 2
• Supporting Health Including Endocrine Treatment for Long DurationRecruitingNCT07482384Not applicable
• Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO StudyRecruitingNCT07123649Phase 2
• The COMPASSION StudyRecruitingNCT06507930Not applicable
• Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerRecruitingNCT06488378Phase 1
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
• TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer PatientsRecruitingNCT05535192Not applicable
• Scalp Cooling in MBCRecruitingNCT04986579Phase 2
• ATEMPT 2.0: Adjuvant T-DM1 vs THRecruitingNCT04893109Phase 2
• Refining Local-Regional Therapy for IBCRecruitingNCT04636710Not applicable
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCRecruitingNCT04468061Phase 2
• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingNCT04434040Phase 2
• TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingNCT06001762Phase 2Results posted
• Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)CompletedNCT05011279Not applicableResults posted
• Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical ActivityCompletedNCT04717050Not applicableResults posted
• Niraparib + Dostarlimab In BRCA Mutated Breast CancerActive, not recruitingNCT04584255Phase 2Results posted
• MARGetuximab Or Trastuzumab (MARGOT)Active, not recruitingNCT04425018Phase 2Results posted
• Individualizing Surveillance Mammography for Older Breast Cancer SurvivorsCompletedNCT03865654Not applicableResults posted
• NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerActive, not recruitingNCT03789110Phase 2Results posted
• Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled TrialCompletedNCT03783546Not applicableResults posted
• GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain MetastasesTerminatedNCT03765983Phase 2Results posted
• ATOP TRIAL: T-DM1 in HER2 Positive Breast CancerActive, not recruitingNCT03587740Phase 2Results posted
• Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain MetastasisCompletedNCT03483012Phase 2Results posted
• Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast CarcinomaActive, not recruitingNCT03422003Not applicableResults posted
• Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast CancerCompletedNCT03414684Phase 2Results posted
• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerCompletedNCT03316586Phase 2Results posted
• Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast CancerTerminatedNCT03289039Phase 2Results posted
• Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility StudyCompletedNCT03170648Not applicableResults posted
• Palbociclib After CDK and Endocrine Therapy (PACE)Active, not recruitingNCT03147287Phase 2Results posted
• Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast CancerTerminatedNCT03130439Phase 2Results posted
• PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical LesionsActive, not recruitingNCT03070236Not applicableResults posted
• Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BCTerminatedNCT03051672Phase 2Results posted
• A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast CancerCompletedNCT03051659Phase 2Results posted
• A Study Of Pembrolizumab In Combination With Trastuzumab-DM1CompletedNCT03032107Phase 1Results posted
• CISPLATIN + AZD-1775 In Breast CancerCompletedNCT03012477Phase 2Results posted
• Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant TherapyCompletedNCT02956473Not applicableResults posted
• Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerCompletedNCT02876302Phase 2Results posted
• Palbociclib With Everolimus + Exemestane In BCCompletedNCT02871791Phase 1/2Results posted
• Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)Active, not recruitingNCT02764541Phase 2Results posted
• Avoiding Growth Factor During Paclitaxel Treatment in Breast CancerCompletedNCT02698891Phase 2Results posted
• An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.CompletedNCT02657343Phase 1/2Results posted
• A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast CancerCompletedNCT02448771Phase 1/2Results posted
• T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAActive, not recruitingNCT02326974Phase 2Results posted
• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesCompletedNCT02260531Phase 2Results posted
• Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast CancerTerminatedNCT02137252Phase 2Results posted
• Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory BrcaCompletedNCT02041429Phase 1/2Results posted
• Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCompletedNCT02040857Phase 2Results posted
• Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerTerminatedNCT01912963Phase 2Results posted
• T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)CompletedNCT01853748Phase 2Results posted
• Eribulin in HER2 Negative Metastatic BrCaCompletedNCT01827787Phase 2Results posted
• Melatonin Versus Placebo in Breast CancerCompletedNCT01805089Early Phase 1Results posted
• Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCaCompletedNCT01796197Phase 2Results posted
• BKM120 For Triple Negative Breast CancerCompletedNCT01790932Phase 2Results posted
• Cabozantinib for Metastatic Triple Negative BrCaCompletedNCT01738438Phase 2Results posted
• Ruxolitinib in Patients With Breast CancerTerminatedNCT01562873Phase 2Results posted
• Fulvestrant With or Without Ganetespib in HR+ Breast CancerCompletedNCT01560416Phase 2Results posted
• HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesCompletedNCT01494662Phase 2Results posted
• Exercise and Metformin in Colorectal and Breast Cancer SurvivorsCompletedNCT01340300Phase 2Results posted
• Trastuzumab and Vinorelbine in Advanced Breast CancerTerminatedNCT01185509Phase 2Results posted
• Carboplatin and Bevacizumab for Progressive Breast Cancer Brain MetastasesCompletedNCT01004172Phase 2Results posted
• Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast CancerTerminatedNCT00925652Phase 2Results posted
• Extended Endocrine Therapy for Premenopausal Women With Breast CancerCompletedNCT00903162Phase 2Results posted
• Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast CancerCompletedNCT00880464Phase 1Results posted
• Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast CancerCompletedNCT00542451Phase 2Results posted
• Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer PatientsCompletedNCT00317603Phase 1Results posted
• Letrozole in Preventing Breast Cancer in Postmenopausal WomenCompletedNCT00090857Phase 2Results posted
• Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational InterventionCompletedNCT07519200Not applicable
• Dance Study for Post-surgical Pain in Breast Cancer SurvivorsActive, not recruitingNCT06758102Not applicable
• Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)Active, not recruitingNCT06322888Not applicable
• INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine TherapyCompletedNCT06246084Not applicable
• Implantable Microdevice for TNBC - Pilot StudyWithdrawnNCT05774886Phase 1
• STOP-HER2: Stopping Trastuzumab in HER2+ MBCActive, not recruitingNCT05721248Phase 2
• Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)Active, not recruitingNCT05629065Not applicable
• Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)CompletedNCT05528263Not applicable
• Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE StudyActive, not recruitingNCT05327452Not applicable
• Video Education With Result Dependent dIsclosureCompletedNCT05225428Not applicable
• Axillary Lymph Node Tattoo Marking StudyTerminatedNCT04947917Not applicable
• TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)CompletedNCT04936243Not applicable
• Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing ChemotherapyActive, not recruitingNCT04724499Not applicable
• Taking AIM at Breast CancerActive, not recruitingNCT04720209Not applicable
• Feasibility of Fasting & Exercise in Pts With HR+ MBCCompletedNCT04708860Not applicable
• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerActive, not recruitingNCT04569747Phase 2
• YES Study - Newly Diagnosed/Metastatic InterventionActive, not recruitingNCT04379414Not applicable
• Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention PilotCompletedNCT03913936Not applicable
• 'ADVANCE' (A Pilot Trial)Active, not recruitingNCT03858322Phase 1
• Tucatinib + Abemaciclib + Herceptin for HER2+ MBCWithdrawnNCT03846583Phase 1
• Elevate! : An Elderly Breast Cancer Cohort StudyActive, not recruitingNCT03818087
• Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast CancerCompletedNCT03749421
• DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCActive, not recruitingNCT03716180Phase 1
• Physical Activity, Proliferation and Immune Markers in Benign Breast TissueActive, not recruitingNCT03657628Not applicable
• Olaparib + Sapacitabine in BRCA Mutant Breast CancerActive, not recruitingNCT03641755Phase 1
• Sexual Health and Rehabilitation After Ovarian Suppression TreatmentCompletedNCT03571841Not applicable
• Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse BackgroundsCompletedNCT03447886
• Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTerminatedNCT03294694Phase 1
• Qigong For PPSP In Breast Cancer Pain In Breast Cancer SurvivorsCompletedNCT02848989Not applicable
• Evaluation Of Lymph Nodes After Neoadjuvant ChemotherapyWithdrawnNCT02752009Not applicable
• Improving Surgical Decision-making in Young Women With Breast CancerCompletedNCT02644382